Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment

• Lexaria, a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM) technology for the oral delivery of glucagon-like peptide-1 (“GLP-1”) drugs.
• GLP-1 drugs have shown great promise in addressing diabetes and obesity, with nearly all the major brands administered only through injection devices.
• A previous human study by Lexaria evidenced improved bioavailability when semaglutide was administered orally, as compared to standard Rybelsus®.
• Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP1 market.

Data from the United States shows that 54% of adults and 66% of children consume more added sugars than recommended (https://ibn.fm/W2oXd). On average, it has been noted that adults, young adults, and children in the United States consume 17 teaspoons of added sugar daily, which is more than two to three times the recommended amount for men and women, respectively. Extrapolated annually, this adds up to around 60 pounds of added sugar or six 10-pound bowling balls (https://ibn.fm/Dah7s).

Numerous studies have linked increased sugar consumption to diabetes. While not directly linked, sugar is considered integral to weight gains, which, in turn, increases their risk of type 2 diabetes. The condition cannot be cured, but it can be managed. Recent studies on glucagon-like peptide-1 (“GLP-1”) have shown great promise in addressing the condition. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the potential of these GLP-1 drugs, and if any of its recent studies are anything to go by, the company is on track to offer an oral delivery enhancement to current GLP-1 options that are in the market today.

People living with diabetes often require insulin shots to manage their condition. Although many types of insulin are available, including long-acting, rapid-acting, and short-acting, none of those can be taken orally to lower blood sugar. This is because stomach enzymes have been shown to interfere with insulin’s action, prompting the use of needles and syringes, or an insulin pen, to deliver the product to the body (https://ibn.fm/5LCz7). This has also been the case for GLP-1 drugs.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/RxUBh).

Lexaria has explored oral delivery of GLP-1 drugs using its patented DehydraTECH(TM) technology since the beginning of the year. So far, its studies have evidenced increased bioavailability, with its WEIGHT-A24-1 diabetes animal study showing a stark decrease in the rate of body weight gain for specific DehydraTECH-CBD formulations and noticeable weight loss for its DehydraTECH-Liraglutide (https://ibn.fm/iB9NN). All of its studies thus far have highlighted DehydraTECH’s potential in treating diabetes and obesity, and the company looks to double down on this research for the remainder of the year.

As the conversation about added sugars, diabetes, and obesity proliferates, the company’s management is optimistic about its ongoing GLP-1 studies. It is also confident that the studies will yield positive results, demonstrating the superiority of DehydraTECH as a drug delivery technology. As a company, Lexaria has already validated the technology’s usefulness in delivering various orally administered bioactive molecules more effectively. Its focus on GLP-1 drugs for the potential treatment of diabetes and obesity speaks to the company’s confidence in the technology and its commitment to stamping its position as a leader in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is powered by IBN